SLU-PP-332 is not a peptide. It is a small synthetic molecule, 4-hydroxy-N-[(E)-naphthalen-2-ylmethylideneamino]benzamide, with the formula C18H14N2O2 and a molecular weight of 290.3, developed in Thomas Burris's laboratory at Saint Louis University as a pan-agonist of the estrogen-related receptors ERRα, β and γ and described by its makers as an exercise mimetic. It is sold through the research-peptide channel, in lyophilized vials of 5, 10 and 20 mg and as capsules, which is why searches for its dosage land beside peptide pages and why it has a calculator on this site. Nothing about peptides transfers to it, and, more to the point of this page, nothing about a human dose exists for it at all.
This page documents that absence with the counts and dates a reader can check, reports the mouse figures the two primary papers used, scales them so the reader can see how far the circulating figures sit from them, and does the vial arithmetic for the three vial sizes. It recommends nothing. The SLU-PP-332 calculator runs the same sums for any vial and volume, and the dosage hub indexes every compound this site covers. The SLU-PP-332 reconstitution page works the vial presentation from water volume to concentration and units.
What does not exist
- DailyMed: no record on 2026-09-18.
- ClinicalTrials.gov: no study with SLU-PP-332 as an intervention or as a search term.
- PubMed: ten records in total on 2026-09-18, none tagged as a clinical trial. Two are the primary mouse papers, one is a 2026 mouse paper on the successor compound, one is a 2024 heart-failure paper in mice, one a 2023 aging-kidney paper in mice, one a 2026 structure-activity paper, one a 2026 Spanish-language review, two are 2026 doping-control metabolite studies done in vitro, and one is a 2025 pilot study that treated cultured myoblasts from the muscle biopsies of 20 women (PMID 40692696), which is the only record involving human material and involves no person receiving the compound.
- No human pharmacokinetics, no human safety observation, no human dose-response, in any record.
What the mouse papers used
| Paper | Model | Dose and route | Frequency and duration | Animals per group |
|---|---|---|---|---|
| Billon and colleagues, ACS Chemical Biology, 2023 (PMID 36988910) | male C57BL/6J mice | 30 or 50 mg/kg, intraperitoneal | single dose one hour before treadmill testing, or twice daily for 7 to 15 days | 6 to 8 |
| Billon and colleagues, Journal of Pharmacology and Experimental Therapeutics, 2024 (PMID 37739806) | C57BL/6J mice on chow or a high-fat diet; ob/ob mice | 50 mg/kg, intraperitoneal | twice daily; 28 days on the high-fat diet, 12 days in ob/ob mice | 7 to 10 |
Both full texts were read at PubMed Central on 2026-09-18. The 2023 paper also reports the exposure the dose produced: two hours after 30 mg/kg intraperitoneally, about 0.6 µM in skeletal muscle and 0.2 µM in plasma. The 2024 paper reported reduced fat mass, higher energy expenditure and fatty-acid oxidation, and improved insulin sensitivity in the obese models. Neither paper administered the compound by mouth, and the 2026 paper introducing SLU-PP-915 states plainly that SLU-PP-332 lacks oral bioavailability (PMID 41421047).
Scaling the mouse dose, and why it matters here
A mouse mg/kg figure is not a human mg/kg figure. The convention used for first-in-human dose estimates converts by body surface area, dividing a mouse dose by 12.3, the ratio of the human and mouse Km factors of 37 and 3 (Nair and Jacob, Journal of Basic and Clinical Pharmacy, 2016, 7(2):27-31, read 2026-09-18).
| Mouse figure | Human-equivalent dose | For a 70 kg adult |
|---|---|---|
| 30 mg/kg, single | 2.4 mg/kg | about 170 mg |
| 50 mg/kg, single | 4.1 mg/kg | about 285 mg |
| 50 mg/kg twice daily | 8.1 mg/kg per day | about 570 mg per day |
Simple weight scaling, which the convention rejects, would give 3.5 g per 50 mg/kg dose. Against either figure, the amounts that circulate on vendor, clinic and forum pages on 2026-09-18, 250 mcg to 1 mg per day by mouth and 500 to 1,500 mcg per day by injection, are 570 to 2,300 times smaller by the surface-area method. The point of the arithmetic is not that a larger figure would be right; it is that the circulating figures cannot have come from the only in-vivo data that exist, and no page citing them says where they did come from. They are also mostly oral, for a compound its developers report is not orally available.
The figures that circulate
The pages read on 2026-09-18 clustered at 250 to 500 mcg per day for fat loss and 1 to 1.5 mg per day for performance, sometimes divided into two or three doses, with courses of a few weeks; injectable pages gave 500 to 1,500 mcg per day. Several of the same pages state that no human trial exists, and then give a figure anyway. Peptifact's SLU-PP-332 page reads the same sources from the journalism side, and this site's 5-Amino-1MQ calculator covers the other small molecule that circulates through the peptide channel with the same kind of figure and the same kind of gap.
The arithmetic per vial
The calculator applies to the lyophilized vial, not to a capsule. Concentration in mcg/mL is the vial amount divided by the water volume; micrograms per unit is that figure divided by 100, because a U-100 syringe holds 100 units in 1 mL and each small notch on a standard 1 mL insulin syringe is 1 unit (MedlinePlus, reviewed 2024-07-21). The columns are the circulating figures, converted, not endorsed. The calculator notes on this site record that vials sometimes carry a co-solvent such as DMSO because the molecule dissolves poorly in water; the arithmetic does not change, but the vial's label is the only authority on what is in it.
| Vial and water | mcg/mL | mcg per unit | 250 mcg | 500 mcg | 1,000 mcg |
|---|---|---|---|---|---|
| 5 mg in 1 mL | 5,000 | 50 | 5 units | 10 | 20 |
| 5 mg in 2 mL | 2,500 | 25 | 10 | 20 | 40 |
| 5 mg in 3 mL | 1,667 | 16.7 | 15 | 30 | 60 |
| 10 mg in 1 mL | 10,000 | 100 | 2.5 | 5 | 10 |
| 10 mg in 2 mL | 5,000 | 50 | 5 | 10 | 20 |
| 10 mg in 3 mL | 3,333 | 33.3 | 7.5 | 15 | 30 |
| 20 mg in 1 mL | 20,000 | 200 | 1.25 | 2.5 | 5 |
| 20 mg in 2 mL | 10,000 | 100 | 2.5 | 5 | 10 |
| 20 mg in 3 mL | 6,667 | 66.7 | 3.75 | 7.5 | 15 |
The 20 mg vial in 1 mL puts every circulating figure at a fraction of a unit; that is a property of a concentrated mix of a milligram-scale vial, and it is the one thing on this page that has nothing to do with the absence of human data.
What the figures omit
The mouse figures carry a species, a route no page recommends for a person, a twice-daily frequency, courses of one to four weeks, and endpoints of treadmill endurance and fat mass. They carry no human pharmacokinetics, no bioavailability by any route in humans, no half-life, and no safety observation beyond the papers' statement that the mice tolerated the regimen. Two 2026 analytical papers characterised the molecule's metabolites for doping control (Drug Testing and Analysis; Rapid Communications in Mass Spectrometry), which is a fact about how the compound is being watched, not about a dose. The mechanism, the evidence file and the sourcing belong to Medibact's SLU-PP-332 guide.
Sources and dates
Opened 2026-09-18: PubChem CID 5338394; DailyMed (no record); ClinicalTrials.gov v2 API (no study); PubMed, ten records with the abstracts of PMIDs 36988910, 37739806, 41421047, 40692696, 42024694 and 41850449 read and the full texts of PMC11584170 and PMC10801787 read for the doses; Nair and Jacob, 2016, at PMC4804402; MedlinePlus, "Giving an insulin injection" (reviewed 2024-07-21); vendor, clinic and forum pages for the circulating figures. Vial sizes and the co-solvent note are the calculator preset's.
This page does not recommend a dose, a route, a frequency or a schedule, and it does not say what any figure means for a particular person. It reports that no human dose exists, states the mouse figures and what they scale to, and converts micrograms into syringe units for a vial, which is the whole of what it can honestly do.